December 13, 2012

Gene therapy shows promise in eradicating some blood cancers

Out of 10 patients, only two patients have not gotten better on the T cell therapy, even though all had stopped responding to conventional treatments. Four patients have had a complete response - their leukemia was eradicated - with the longest so far lasting 28 months. In four other patients, leukemia diminished dramatically.

This is the same treatment that was described in a Nextbigfuture article yesterday. Novartis has the rights to this and is developing it.

"We believe we know why the two patients didn't respond," said Penn physician David L. Porter, a cancer and blood specialist. "If we're right, it's something we can fix."

The therapy, culminating 20 years of research, involves genetically engineering T cells - the immune system's big guns - to attack B cells, the blood component that turns malignant in chronic lymphocytic leukemia and acute lymphoblastic leukemia.

Interfering with the immune system, however, is dicey. From the start, it was clear the designer T cells had side effects that caused flulike symptoms.


The modified T cells can attack the patients B cells and set off a self-destructive chain reaction.

The T cells flood the body with signaling chemicals called cytokines, particularly interleukin 6. The interleukin, in turn, stimulated cells called macrophages that normally consume cellular debris.

The macrophages can go on a rampage and consume the patients red blood cells.

A drug tocilizumab (Actemra), a new rheumatoid arthritis drug can stop the dangerous side effects.

Doctors now know how to manage the side effects and they are determining when to provide Actemra to reverse the T cells.

SOURCE - Philly Inquirer


If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks

Congratulations! Now you can use SolidOpinion commenting system in all its magnificence! Click the link to get your password.

Форма для связи

Name

Email *

Message *